HOOKIPA Q2 net loss $18M; HB-200 Phase 2 shows 43% ORR in HPV16+ head and neck cancer

HOOKIPA Pharma Inc.

2023-Q2 EPS reported -$0.49 revenue$5,855,000

Net loss $18.0M in Q2 2023 vs $16.4M in Q2 2022; revenue flat at $2.7M.
Cash $136.0M at June 30, 2023, up from $113.4M at Dec 31, 2022, after $50M June offering.
Phase 2 HB-200 + pembrolizumab: 43% ORR in CPI-naïve patients, double pembrolizumab alone; randomized trial planned H1 2024.
R&D expenses rose $3.6M to $19.7M on higher clinical costs for HB-200, HB-300, and partnered programs.
Exchange offer for 627,632 underwater options (exercise >$6.50) to eligible non-executive employees.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

HOOKIPA Pharma Inc. reported second quarter of 2023 results: revenue $2.7 million.

Period: second quarter of 2023
Revenue: $2.7 million
Result: reported results

Exact text from the filing

The increase was primarily attributable to funds resulting from the follow-on financing in June 2023, partly offset by cash used in operating activities. Revenue: Revenue was $2.7 million for the three months ended June 30, 2023 and for the three months ended June 30, 2022. A decrease of cost reimbursements received under the Restated Gilead Collaboration

View on SEC.gov

Browse all earnings releases →

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-014390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.